Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Conditioning for Haploidentical CD34+ PBSCT
NCT00112567Phase 2Completed
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- Apr 2003
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fludarabine and thiotepa in acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and 1 more, sponsored by Fred Hutchinson Cancer Center. Primary endpoint: Safety of conditioning regimen. Started Apr 2003; status: completed.
02
Drugs
fludarabinethiotepa
03
Conditions
acute lymphoblastic leukemia (ALL)acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT00112567.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00112567.